Table 4.
Association of HLA-B alleles with carbamazepine-induced SJS/TEN.
| HLA-B alleles | Carbamazepine-induced SJS/TEN (n = 16) | Controls (n = 271) | Thai population (n = 470) | Carbamazepine-induced SJS/TEN cases versus tolerant controls | Carbamazepine-induced SJS/TEN cases versus Thai population | ||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||||
| B∗07:05 | 2 (12.50%) | 12 (4.43%) | 24 (5.11%) | 3.08 (0.63–12.13) | 0.165 | 2.65 (0.57–12.35) | 0.213 |
| B∗13:01 | 1 (6.25%) | 37 (13.65%) | 54 (11.49%) | 0.40 (0.05–3.07) | 0.709 | 0.48 (0.06–3.70) | 0.707 |
| B∗15:01 | 1 (6.25%) | 10 (3.69%) | 5 (1.06%) | 1.63 (0.20–13.55) | 0.494 | 5.81 (0.64–52.67) | 0.193 |
| B∗15:02 | 12 (75.00%) | 11 (4.06%) | 71 (15.11%) | 70.91 (19.67–255.65) | 4.46 × 10−13∗ | 18.26 (5.79–57.61) | 6.9 × 10−8∗ |
| B∗15:21 | 2 (12.50%) | 4 (1.48%) | 2 (0.43%) | 9.54 (1.61–56.57) | 0.013∗ | 19.14 (2.51–146.09) | 0.004∗ |
| B∗18:01 | 2 (12.50%) | 29 (10.70%) | 36 (7.66%) | 1.19 (0.26–5.51) | 0.822 | 1.72 (0.38–7.88) | 0.483 |
| B∗18:15 | 1 (6.25%) | 0 (0.00%) | 0 (0.00%) | 16.94 (1.01–183.39) | 0.114 | 29.38 (1.76–490.97) | 0.069 |
| B∗44:03 | 1 (6.25%) | 20 (7.38%) | 42 (8.94%) | 0.78 (0.10–6.22) | 1.000 | 0.37 (0.05–2.89) | 0.484 |
| B∗46:01 | 4 (25.00%) | 64 (23.62%) | 122 (25.96%) | 1.08 (0.34–3.46) | 0.899 | 0.96 (0.30–3.03) | 0.947 |
| B∗56:04 | 1 (6.25%) | 1 (0.37%) | 12 (2.55%) | 16.88 (1.01–282.35) | 0.115 | 2.39 (0.29–19.48) | 0.374 |
| B∗58:01 | 1 (6.25%) | 22 (8.12%) | 57 (12.13%) | 0.71 (0.09–5.59) | 1.000 | 0.45 (0.06–3.48) | 0.707 |
SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis; OR: odds ratio; 95% CI: confidence interval 95%. ∗P value less than 0.05.